Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/successful-treatment-of-brain-metastases-from-renal-cell-cancer-using-QDcjge01Ft
References (6)
-
I. Brownell, W. Fangman (2007)
Hepatitis C virus infection, type III cryoglobulinemia, and necrotizing vasculitis.Dermatology online journal, 13 1
-
H. Gay, R. Cavalieri, R. Allison, J. Finley, W. Quan (2007)
Complete response in a cutaneous facial metastatic nodule from renal cell carcinoma after hypofractionated radiotherapy.Dermatology online journal, 13 4
-
V. Gupta, N. Jaskowiak, M. Beckett, H. Mauceri, Jeremy Grunstein, R. Johnson, D. Calvin, E. Nodzenski, M. Pejovic, D. Kufe, M. Posner, R. Weichselbaum (2002)
Vascular Endothelial Growth Factor Enhances Endothelial Cell Survival and Tumor RadioresistanceThe Cancer Journal, 8
-
J. Brieger, J. Kattwinkel, M. Berres, J. Gosepath, W. Mann (2007)
Impact of vascular endothelial growth factor release on radiation resistance.Oncology reports, 18 6
-
J. Plastaras, Seok-Hyun Kim, Yingqiu Liu, D. Dicker, J. Dorsey, J. McDonough, G. Cerniglia, R. Rajendran, Anjali Gupta, A. Rustgi, J. Diehl, Charles Smith, K. Flaherty, W. El-Deiry (2007)
Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation.Cancer research, 67 19
-
Chang Lee, M. Heijn, E. Tomaso, G. Griffon-Etienne, M. Ancukiewicz, C. Koike, K. Park, N. Ferrara, R. Jain, H. Suit, Y. Boucher (2000)
Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions.Cancer research, 60 19
- Publisher
- Springer Journals
- Copyright
- Copyright © 2008 by Springer-Verlag
- Subject
- Medicine & Public Health; Biomedicine general; Oncology
- ISSN
- 1776-2596
- eISSN
- 1776-260X
- DOI
- 10.1007/s11523-008-0091-8
- Publisher site
- See Article on Publisher Site
Abstract
Sorafenib, an antiangiogenic drug, has been introduced for treatment of disseminated renal cell cancer (RCC), a tumor that is radioresistant. We report a case of 51-year-old patient with disseminated RCC who received 30 Gy per ten fractions of radiotherapy (RT) for a single brain metastasis. While the brain metastasis remained stable, the patient had to receive interferon-alpha and later sorafenib due to progression of his extra-cerebral metastases. During sorafenib therapy, complete remission of the cerebral lesion and excellent partial remission of the extra-cerebral metastases were observed. Meanwhile, the patient developed a second cerebral metastasis, which was irradiated only with 20 Gy per ten fractions during a short break in the sorafenib treatment. The follow-up computed tomographies revealed complete remission of the second metastasis and development of brain necrosis in a moderately irradiated area. The case of this patient being his own control demonstrates sorafenib-mediated potentiation of RT effects both in tumor and normal tissues.
Journal
Targeted Oncology – Springer Journals
Published: Oct 8, 2008